trending Market Intelligence /marketintelligence/en/news-insights/trending/oS2rffwl-diWKbcbpe3yxg2 content esgSubNav
In This List

CBT Pharmaceuticals rebrands to Apollomics, raises $100M for cancer programs

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


CBT Pharmaceuticals rebrands to Apollomics, raises $100M for cancer programs

CBT Pharmaceuticals Inc., which will now be called Apollomics Inc., has raised about $100 million in a Series B financing for its cancer drug programs and the exploration of new treatment areas.

The company also announced the corporate name change, which President Sanjeev Redkar said in a Jan. 7 press release is in line with its efforts to eradicate cancer.

China Merchants Bank Co. Ltd. unit CMB International led the funding round, which also included existing investor OrbiMed Asia and some new investors. In line with the fundraising, Kexiang Zhou, the managing director of CMB International, has been appointed to the Apollomics board.

Apollomics, which develops medicines that target the growth of cancer cells, plans to relocate its headquarters to Foster City, Calif., to help with its U.S. expansion.